WO2006008833A1 - 茶ポリフェノール組成物及びその製造方法 - Google Patents
茶ポリフェノール組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2006008833A1 WO2006008833A1 PCT/JP2004/012052 JP2004012052W WO2006008833A1 WO 2006008833 A1 WO2006008833 A1 WO 2006008833A1 JP 2004012052 W JP2004012052 W JP 2004012052W WO 2006008833 A1 WO2006008833 A1 WO 2006008833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tea
- gallate
- tea polyphenol
- polyphenol composition
- gallocatechin
- Prior art date
Links
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 69
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims description 57
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000005487 catechin Nutrition 0.000 claims abstract description 45
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 35
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 31
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 30
- 150000001765 catechin Chemical class 0.000 claims abstract description 30
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 24
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims abstract description 17
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims abstract description 15
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 14
- 229950001002 cianidanol Drugs 0.000 claims abstract description 14
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims abstract description 13
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims abstract description 8
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims abstract description 7
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims abstract description 7
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000012734 epicatechin Nutrition 0.000 claims abstract description 6
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 6
- 241001122767 Theaceae Species 0.000 claims abstract 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 26
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 229920005989 resin Polymers 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 17
- 238000001179 sorption measurement Methods 0.000 claims description 17
- 229960001948 caffeine Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 13
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 12
- 238000003809 water extraction Methods 0.000 claims description 8
- 229940074391 gallic acid Drugs 0.000 claims description 5
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 235000019606 astringent taste Nutrition 0.000 abstract description 25
- 235000019658 bitter taste Nutrition 0.000 abstract description 24
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 description 127
- 235000013616 tea Nutrition 0.000 description 121
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 38
- 238000000605 extraction Methods 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 17
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 16
- 239000012528 membrane Substances 0.000 description 13
- 235000019640 taste Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 235000009569 green tea Nutrition 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001766 physiological effect Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000010409 thin film Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 4
- -1 polyphenol catechins Chemical class 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019225 fermented tea Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KBPZVLXARDTGGD-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;iron Chemical compound [Fe].OC(=O)C(O)C(O)C(O)=O KBPZVLXARDTGGD-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a tea polyphenol composition with improved taste such as bitterness * astringency and a method for producing the same.
- Tea polyphenol catechins have an antioxidant effect (JP 59-219384, JP 1-268683), antibacterial and bacteriostatic action (JP 2-276562, JP 3-276). No. 246227), Cholesterol elevation inhibitory action (JP-A-60-156614), Blood pressure elevation inhibitory production (JP-A No. 63-214183), Blood sugar elevation inhibitory action (JP-A-4-253918) It is known to have various effects.
- a gel column using a method of purifying a high-purity polyphenolic compound (strengthen) by contacting with lignocellulose see Patent Document 1
- an aqueous solution of a hydrophilic organic solvent with an appropriately changed concentration Chromatographic separation of impurities to produce tea catechin compounds in high yield see Patent Document 2
- caffeine contained in tea leaves is passed through a chromatographic column packed with an adsorbent such as cyclodextrin polymer
- an adsorbent such as cyclodextrin polymer
- Patent Document 1 Japanese Patent Laid-Open No. 7-238078
- Patent Document 2 JP-A-1-175978
- Patent Document 3 Japanese Patent Laid-Open No. 10-67771
- an object of the present invention is to overcome the above-mentioned problems and to provide a tea polyphenol composition in which bitterness and astringency are alleviated in spite of the high purity of catechins. It is to provide an efficient manufacturing method.
- the present inventors have a high purity content of catechins by containing the component composition in the tea polyphenol composition at a specific ratio. Nevertheless, the present inventors have found that an excellent tea polyphenol composition with reduced bitterness and astringency can be obtained, and have completed the present invention based on strong knowledge.
- the present invention according to claim 1 provides:
- A 85 to 95% by weight of strength techins
- B 65 to 80% by weight of epigallocatechin gallate and gallocatechin gallate in catechins
- C epigaro Catechin gallate + gallocatechin gallate
- Z Epicatechin + catechin + epigallocatechin + galocatechin + epicatechin gallate + force techin gallate
- A 85 to 95% by weight of strength techins
- B 65 to 80% by weight of epigallocatechin gallate and gallocatechin gallate in catechins
- C epigaro Catechin gallate + gallocatechin gallate
- Z Epicatechin + catechin + epigallocatechin + galocatechin + epicatechin gallate + force techin gallate
- the ratio represented by (epigacatechin gallate + epicacatechin gallate + gallo force techin gallate + force techin gallate) Z (epicacatechin + epigalocatechin + gallocatechin + catechin) is 37.
- the present invention according to claim 3 is characterized in that the ratio represented by (epigacatechin gallate + gallocatechin gallate) Z (epicacatechin + epigalocatechin + gallocatechin + catechin) is 2-6. Polyphenol composition.
- the present invention according to claim 4 is the tea polyphenol composition according to claims 1 to 3, wherein catechins contain 2 to 15% by weight of gallocatechin gallate, gallocatechin, force techin gallate and catechin.
- the present invention according to claim 5 is a tea polyphenol composition according to claims 1 to 4, wherein the ratio represented by Epigalocatechin Gallate / (Epicatechin + Epigalocatekine + Epicatechin Gallate) is 2-4. It is.
- the present invention according to claim 6 is the tea polyphenol composition according to any one of claims 1 to 5, which contains 0.0001-1.2% by weight of caffeine.
- the present invention according to claim 7 is the tea polyphenol composition according to any one of claims 1 to 6, wherein the ash content is 0.0001 to 0.2% by weight.
- the present invention according to claim 8 is a tea polyphenol composition according to claims 1 to 7, wherein the gallic acid is not contained.
- the present invention according to claim 9 is the method for producing a tea polyphenol composition according to claims 1 to 8 obtained by the following steps 1) to 3).
- the tea polyphenol composition of the present invention contains high purity techins, the excellent physiological effects of catechins such as antioxidant action, antibacterial 'bacteriostatic action, cholesterol rise inhibitory action, blood pressure rise inhibitory effect It is possible to more effectively exert the action, the blood glucose rise inhibiting action, and the like.
- the tea polyphenol composition of the present invention has excellent palatability such as improved taste such as bitterness and astringency.
- catechins are epigallocatechin gallate (hereinafter referred to as EGCg), epigallocatechin (hereinafter referred to as EGC), epicatechin gallate (hereinafter referred to as ECg), epicatechin (hereinafter referred to as EC). ), Gallocatechin gallate (hereinafter referred to as GCg), gallocatechin (hereinafter referred to as GC), force techin gallate (hereinafter referred to as Cg) and force techin (hereinafter referred to as C). is there.
- EGCg epigallocatechin gallate
- EGC epigallocatechin
- ECg epicatechin gallate
- ECg epicatechin gallatechin
- Cg force techin gallate
- C force techin
- These force techins can be either (+) or (one), preferably (1) _EGCg, (1) _EGC, (1) _ECg, (-) -EC , (-)-GCg, (-) _GC, (-)-Cg and (+)-C.
- the tea polyphenol composition of the present invention according to claim 1 contains 85 to 95% by weight of this strength, preferably 85.5 to 94.5% by weight, more preferably 86%. — 94% by weight, more preferably 86.5-93.5% by weight. If the content of catechins is within this range, a large amount of strong techins can be easily taken and the original flavor of tea can be obtained immediately.
- the concentrations of catechins are defined based on the total amount of EGCg, EGC, ECg, EC, GCg, GC, Cg, and C in total.
- EGCg and GCg are added to 65- it is necessary to contain 80 wt%, preferably 66 - 79 wt%, more preferably 67 79 weight 0/0, more preferably from 68 78.5 wt 0/0.
- the total concentration of EGCg and GCg is expressed as EC, C, EGC and GC. It is preferable that the value divided by the sum of the ECg and Cg concentrations is 2-4. 2. 1-3.9 is more preferable 2. 2-3.8 Is more preferred 2. Most preferred is 3-3.7.
- the total concentration of EGCg, ECg, GCg, and Cg is calculated as the concentration of EC, EGC, GC, and C.
- Total value (non-ga It is preferable that the value divided by rate physical strength is 3-7. 3. 1 is 1-6. 8 is more preferable. 3. 1-6. 6 is more preferable. 3. 2-6. 4 is the most preferred. Within this range, the excellent physiological effects of catechins are readily exerted, and taste such as astringency and bitterness is alleviated, which is preferable.
- the total concentration of EGCg and GCg is expressed as EC and EGC. It is preferable that the value obtained by dividing the total concentration of GC and C (non-gallate physical strength techins) is 26. It is more preferable that it is 2.5-5. More preferably, 2.9-5.6 is most preferable.
- GCg, GC, Cg, and C are added to catechins in order to improve the flavor. It is preferable to contain 15% by weight 2. 2-13% by weight is more preferable 2.5-5% to 11% by weight S More preferable 2. 7-10. 4% by weight Most preferably it is.
- EGCg / (EC + EGC) is used to improve the taste of bitterness, astringency, etc.
- + ECg) is preferably a weight ratio of 2-4, more preferably 2. 2-3.9, and even more preferably 2.1-3.
- the 0-0001- 1 - 2 wt 0/0 is preferably from preferably fixture contain caffeine 0 001— 1. Contains 2% by weight. If the caffeine content exceeds 1.2% by weight, depending on the intake and individual differences, caffeine's strong physiological effects may cause dizziness, insomnia, increased heartbeat, and nausea.
- the ash content preferably 0. 0001- 0. 2 wt 0/0, more preferably 0.001 0 . to 2 wt 0/0, preferred for improving astringent, a taste, such as bitter.
- gallic acid (garlic acid) is not included in order to more effectively exhibit the excellent physiological effect of catechins. It is preferable.
- those having all the requirements described in claims 1 to 8 are combined with particularly preferable ranges that are preferable for improving taste such as astringency and bitterness. More preferred is
- tea polyphenol composition according to claims 1 to 8 as described above can be produced by the method of the present invention according to claim 9, for example.
- the present invention according to claim 9 is the method for producing a tea polyphenol composition according to claims 1 to 8 obtained by the following steps 1) to 3).
- the tea polyphenol in the present invention refers to a polyphenol-containing extract extracted from tea leaves or a purified polyphenol compound.
- tea leaves as used herein means leaves derived from Camellia sinensis, which belongs to the camellia family. Fermented teas such as ready-made black tea and puerh tea, regardless of whether they are fermented or non-fermented, It may be any one of semi-fermented teas such as tea and baked tea, non-fermented teas such as green tea, pot-roasted green tea, and roasted tea, or a mixture of two or more of these.
- the polyphenol of the present invention can be measured by a colorimetric method using iron tartrate. However, in order to measure the composition of tea polyphenol in detail, it is preferably measured by reverse phase high performance liquid chromatography.
- the tea leaves used in the present invention may be either fresh or dried, but it is particularly preferable to use dried products.
- the tea leaves may be dried and then pulverized as necessary to prepare for extraction. For example, it can be prepared by drying the tea leaves as they are and then crushing them, or cutting them as they are and then drying them.
- the present invention according to claim 9 includes three steps 1), 1) and 3).
- the first step is a step (extraction step) of supplying tea extract by extracting tea components containing power techins from tea leaves by hot water extraction and further extracting with an organic solvent.
- this extraction step first, the tea component containing the strength teakins is extracted by the above-described tea leaf force hot water extraction.
- the hot water temperature at this time is not particularly limited as long as it is 100 ° C or less under normal pressure, but 60 ° C—100 ° C force S is preferable, 70—90 ° C force S is more preferable, 80—85 ° C is the most preferred. If extraction is performed at a temperature higher than 100 ° C, structural changes such as isomerization polymerization of catechins may occur, which is not preferable.
- the extraction can be performed at a temperature lower than the extraction temperature under normal pressure, and the extraction temperature may be adjusted appropriately according to the pressure level.
- the amount of hot water used for tea leaf extraction is not particularly limited, but it is preferable to use 3 to 10 times the amount of hot water by weight with respect to the amount of tea leaves. preferable. If the amount of hot water used is less than 3 times the weight of tea leaves, sufficient extraction cannot be performed.On the other hand, if the amount of hot water used exceeds 10 times, no particular increase in extraction efficiency is observed. .
- the hot water extraction may be performed only once or repeated twice or more, but the extraction is preferably performed twice.
- the amount of hot water for the second extraction is not particularly limited, but the first extraction is 7 times the weight of the tea leaves, and the second extraction is 5 times the weight of the tea leaves. preferable.
- the liquid to be extracted obtained by the hot water extraction as described above is once cooled.
- the cooling temperature is preferably 50 ° C or lower, more preferably 30 ° C or lower, and further preferably 15 ° C or lower. If the cooling temperature exceeds 50 ° C, the insoluble component is not sufficiently removed during centrifugal filtration performed in the subsequent step, which is preferable.
- the concentration method may be a generally performed method, for example, any of the decompression type concentration method, the upper pressure type concentration method, the heating type concentration method, the batch type concentration method, the membrane type concentration method, the circulation type concentration method, and the like. However, it is preferably carried out by a membrane concentration method, particularly a membrane concentration method using an R membrane. Moreover, there is no problem even if filter filtration or centrifugal filtration is performed before concentration.
- a tea component containing force techins is extracted from tea leaves by hot water extraction, and the obtained liquid to be extracted is preferably cooled and concentrated, and then obtained.
- the concentrated solution is further extracted with an organic solvent.
- Examples of the organic solvent used at this time include acetonitrile, methanol, and ethanol. , Ethyl polyacetate soluble organic solvents such as ethyl acetate, acetone, methyl ethyl ketone, methyl isobutyl ketone, tetrahydrofuran and dioxane, or mixed organic solvents such as these. preferable.
- the amount of the organic solvent is preferably 0.5 to 5 times the volume ratio of the liquid to be concentrated. 1 to 3 times the amount is more preferred. 1.5 The 2 times amount is most preferred. If the amount of organic solvent is less than 0.5 times the concentration of the liquid to be concentrated, sufficient extraction of catechins cannot be performed. On the other hand, if the amount exceeds 5 times, no particular increase in extraction efficiency is observed.
- the concentration method at this time may be a generally performed method, such as a vacuum concentration method, an upper pressure concentration method, a heating concentration method, a batch concentration method, a membrane concentration method, or a circulation concentration method. This can be done by a method.
- any of the above-described methods may be used in combination, and it is particularly preferable to carry out a combination of a vacuum concentration method, a heating concentration method and a circulation concentration method.
- a tea extract (crude tea extract) can be obtained.
- the drying method at this time is not particularly limited, but may be performed by a spray drying method, a freeze drying method, a vacuum drying method, or the like. At this time, there is no particular problem even if a commercial product is used as the crude tea extract.
- the second step is a step of attaching the tea extract (crude tea extract) obtained in the first step to the synthetic adsorption resin.
- the obtained crude tea extract is preferably dissolved in a 5-15% alcohol aqueous solution, more preferably a 10% alcohol aqueous solution, particularly preferably a 10% methanol aqueous solution, and then a synthetic adsorption resin.
- a 5-15% alcohol aqueous solution more preferably a 10% alcohol aqueous solution, particularly preferably a 10% methanol aqueous solution, and then a synthetic adsorption resin.
- the synthetic adsorption resin preferably to use those crosslinked styrene instrument example, HP one 2 0 (Diaion, Mitsubishi Kasei Co., Ltd.), (manufactured by Mitsubishi Kasei Corporation) Sepabeads, Anbara site (Onoregano ), Shodettas (manufactured by Showa Denko KK), Cefadex (manufactured by Pharmacia), and the like.
- the third step is 5-15 synthetic resin. / 0 After washed out with alcohol aqueous solution, eluting the tea force catechins by passing liquid 30 50% aqueous alcohol.
- catechin is prepared by passing a 30% 50% aqueous alcohol solution. However, wash away unadsorbed components before elution with 30% -50% alcohol aqueous solution.
- the synthetic adsorption resin is washed out with 5-15% alcohol aqueous solution, and unadsorbed components are washed away.
- concentration of the aqueous alcohol solution used at this time is 5% -15%, preferably 10%.
- the flow rate of the aqueous alcohol solution may be 50 L or more with respect to a column volume of 300 L.
- the tea strength tekins are eluted by passing a 30-50% aqueous solution of alcohol.
- the alcohol aqueous solution used at this time is not particularly limited, but a methanol aqueous solution is preferable.
- the concentration of the aqueous alcohol solution may be 30% to 50%, preferably 35% to 45%, and more preferably 40%. Therefore, the tea power tekins are preferably eluted using a 40% aqueous methanol solution.
- the flow rate of the aqueous alcohol solution is preferably 280 ⁇ 56 L as long as it is 100 L or more for a column volume of 300 L.
- an insoluble component such as caffeine is washed and removed using an aqueous alcohol solution.
- the alcohol aqueous solution used at this time does not matter, but a methanol aqueous solution is preferred. If the concentration of the aqueous alcohol solution is 50% -100%, 60% -80% is preferable, and 70% is more preferable.
- the flow rate of the aqueous alcohol solution is preferably 100 L or more, more preferably 600 L or more, more preferably 100 L or more with respect to a column volume of 300 L.
- the recovery of the tea catechin fraction starts when (1) -EGCg is (1) -EGC more than 2 times, preferably more than 5 times, and ends at (-) -EGCg ( -)
- the time when -ECg is reached, or when the force fein is 5%, preferably 1%, is good. If the collection start time is further advanced, the ( ⁇ )-EGCg content decreases, and if the recovery end time is further delayed, the ( ⁇ )-EGC g content decreases and the caffeine content increases.
- the tea polyphenol composition of the present invention can be obtained by concentrating and drying the tea-powered tekin fraction obtained by the steps as described above.
- the concentration method may be any method that is generally performed, for example, by a method such as a vacuum concentration method, an upper pressure concentration method, a heating concentration method, a batch concentration method, a membrane concentration method, or a circulation concentration method. Just do it.
- any of the above-mentioned concentration methods may be used in combination. It is preferable to carry out a combination of the formula concentration method and the circulation type concentration method.
- the drying method is not particularly limited, but may be performed by a spray drying method, a freeze drying method, a vacuum drying method, or the like.
- the tea polyphenol composition obtained as described above has a significantly reduced taste such as bitterness and astringency peculiar to catechins.
- caffeine since it contains almost no caffeine or gallic acid with a high content ratio of tea catechins having a gallate group, the original action of polyphenols, which is concerned about the negative effects of caffeine described later, for example, It can be expected to give physiological functions such as antioxidant action, antibacterial 'bacteriostatic action, cholesterol elevation inhibitory action, blood pressure rise inhibitory action, blood glucose rise inhibitory action.
- Caffeine is known to have physiological activities such as central nervous excitability, cardiotonic activity, diuretic activity, etc. Depending on the amount of intake and individual differences, caffeine has strong physiological effects that can cause dizziness, insomnia, increased heart rate, Nausea may occur, and it is regarded as a problem by people with caffeine hypersensitivity.
- the tea polyphenol composition of the present invention is very stable chemically, physically and biologically, its application field is not limited.
- food / beverage products, pharmaceuticals, quasi drugs, cosmetics, It can be added to fibers and the like.
- the product of the present invention can be used in combination with vitamins such as tocopherol and vitamin C, antibacterial agents, fungicides, pigments, fragrances, bulking agents and coating agents.
- This fraction was circulated and concentrated with a centrifugal thin film concentrator (Okawahara Seisakusho Co., Ltd.) to obtain about 20 L of a concentrated solution.
- This concentrated liquid was spray-dried with a spray dryer (manufactured by Futaguchi) to obtain 4.8 kg of a tea polyphenol composition, which was designated as Product 2 of the present invention.
- Example 4 (Production of Invention Product 4)
- Example 5 (Production of Invention Product 5)
- Example 6 (Production of Invention Product 6)
- Example 7 (Production of Invention Product 7)
- Comparative Example 1 (Comparative Product 1) is a commercially available polyphenol preparation “Polyphenon-70A (Mitsui Norin Co., Ltd.)”, and Comparative Example 2 (Comparative Product 2) is “Polyphenon-60B (Mitsui Norin Co., Ltd.). ) ”And Comparative Example 3 (Comparative Product 3) used respectively Epigalocatechin Gallate Pure.
- Test Example 1 Bitterness of tea polyphenol composition 'Sensory test on astringency
- a sensory test was conducted using 10 randomly selected men and women as panelists.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES04772013.1T ES2586417T3 (es) | 2004-07-22 | 2004-08-23 | Composición de polifenol de té y proceso para producir el mismo |
US11/631,444 US20070292544A1 (en) | 2004-07-22 | 2004-08-23 | Tea Polyphenol Composition and Method for Producing the Same |
EP04772013.1A EP1770090B1 (en) | 2004-07-22 | 2004-08-23 | Tea polyphenol composition and process for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004214370A JP4702824B2 (ja) | 2004-07-22 | 2004-07-22 | 茶ポリフェノール組成物及びその製造方法 |
JP2004-214370 | 2004-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006008833A1 true WO2006008833A1 (ja) | 2006-01-26 |
Family
ID=35784968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012052 WO2006008833A1 (ja) | 2004-07-22 | 2004-08-23 | 茶ポリフェノール組成物及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070292544A1 (ja) |
EP (1) | EP1770090B1 (ja) |
JP (1) | JP4702824B2 (ja) |
ES (1) | ES2586417T3 (ja) |
WO (1) | WO2006008833A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1891862A1 (en) * | 2006-07-24 | 2008-02-27 | Unilever Plc | Beverage precursor |
CN101686701B (zh) * | 2007-05-24 | 2012-07-04 | 花王株式会社 | 精制绿茶提取物 |
CN114534470A (zh) * | 2022-03-23 | 2022-05-27 | 广东安嘉洁环保服务有限公司 | 一种生态空间净化溶液及其制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1989943B1 (en) | 2006-03-02 | 2011-06-01 | Kao Corporation | Process for producing purified tea extract |
KR101414410B1 (ko) | 2006-12-28 | 2014-07-01 | 카오카부시키가이샤 | 차 추출물 |
JP4866815B2 (ja) * | 2007-09-05 | 2012-02-01 | 花王株式会社 | 精製緑茶抽出物の製造法 |
JP2010095477A (ja) * | 2008-10-17 | 2010-04-30 | Ito En Ltd | リパーゼ阻害剤 |
KR20190048502A (ko) | 2017-10-31 | 2019-05-09 | (주)아모레퍼시픽 | 성분 함량이 변화된 차 추출물을 포함하는 순환기 질환 개선용 조성물 |
ES2802289B2 (es) * | 2019-07-05 | 2021-07-08 | Elpozo Alimentacion S A | Alimentos carnicos con propiedades saludables que incluyen una mezcla de bioactivos naturales |
CN112889939A (zh) * | 2020-12-14 | 2021-06-04 | 皖西学院 | 一种茶多酚制备的工艺 |
CN113170830A (zh) * | 2021-05-11 | 2021-07-27 | 汪健 | 一种儿茶素饮料 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6467771A (en) * | 1987-09-08 | 1989-03-14 | Pioneer Electronic Corp | High-speed search method for disk player |
JPH01175978A (ja) * | 1987-12-29 | 1989-07-12 | Itouen:Kk | 粗カテキン化合物製造方法 |
JPH069607A (ja) * | 1992-04-07 | 1994-01-18 | Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai | 茶カテキン類の製造方法 |
JPH07238078A (ja) * | 1994-02-24 | 1995-09-12 | Taiyo Kagaku Co Ltd | ポリフェノール化合物の精製法 |
JPH07258103A (ja) * | 1993-09-13 | 1995-10-09 | Hu Kye Sung | 抗血栓剤及びその製造方法 |
WO1999053916A1 (en) * | 1998-04-21 | 1999-10-28 | Mitsui Norin Co., Ltd. | Anti-chlamydia agents |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3002919B2 (ja) | 1991-11-25 | 2000-01-24 | 太陽化学株式会社 | 胃炎,胃または十二指腸潰瘍防止組成物 |
US6068862A (en) * | 1993-06-30 | 2000-05-30 | Taiyo Kagaku Co., Ltd. | Tea-derived feed additive and animal feed containing the same |
IT1275905B1 (it) * | 1995-03-14 | 1997-10-24 | Indena Spa | Frazioni polifenoliche di te', loro uso e formulazioni che le contengono |
JPH09132532A (ja) * | 1995-09-06 | 1997-05-20 | Mitsui Norin Kk | 抗生物質の抗菌力増強方法 |
US6063428A (en) | 1996-02-26 | 2000-05-16 | The Procter & Gamble Company | Green tea extract subjected to cation exchange treatment and nanofiltration to improve clarity and color |
US6210679B1 (en) * | 1999-01-07 | 2001-04-03 | Hauser, Inc. | Method for isolation of caffeine-free catechins from green tea |
JP3360073B2 (ja) * | 2001-02-22 | 2002-12-24 | 花王株式会社 | 飲 料 |
JP3403400B1 (ja) | 2001-09-28 | 2003-05-06 | 花王株式会社 | 容器詰飲料 |
JP3378577B1 (ja) | 2001-09-28 | 2003-02-17 | 花王株式会社 | 飲 料 |
EP1557097B1 (en) | 2002-10-28 | 2013-10-23 | Kao Corporation | Method of removing caffeine from caffeine-containing catechin compound composition |
FR2858550B1 (fr) | 2003-08-06 | 2007-05-18 | Oreal | Composition de maquillage de matieres keratiniques notamment de fibres keratiniques, comme les cils. |
JP4015631B2 (ja) | 2004-02-19 | 2007-11-28 | 株式会社 伊藤園 | 容器詰緑茶飲料の製造方法 |
US7829067B2 (en) | 2004-03-03 | 2010-11-09 | Bio-Botanica, Inc. | Method and composition for treating oral bacteria and inflammation |
-
2004
- 2004-07-22 JP JP2004214370A patent/JP4702824B2/ja active Active
- 2004-08-23 WO PCT/JP2004/012052 patent/WO2006008833A1/ja active Application Filing
- 2004-08-23 ES ES04772013.1T patent/ES2586417T3/es active Active
- 2004-08-23 EP EP04772013.1A patent/EP1770090B1/en active Active
- 2004-08-23 US US11/631,444 patent/US20070292544A1/en not_active Abandoned
-
2009
- 2009-12-04 US US12/631,504 patent/US7763291B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6467771A (en) * | 1987-09-08 | 1989-03-14 | Pioneer Electronic Corp | High-speed search method for disk player |
JPH01175978A (ja) * | 1987-12-29 | 1989-07-12 | Itouen:Kk | 粗カテキン化合物製造方法 |
JPH069607A (ja) * | 1992-04-07 | 1994-01-18 | Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai | 茶カテキン類の製造方法 |
JPH07258103A (ja) * | 1993-09-13 | 1995-10-09 | Hu Kye Sung | 抗血栓剤及びその製造方法 |
JPH07238078A (ja) * | 1994-02-24 | 1995-09-12 | Taiyo Kagaku Co Ltd | ポリフェノール化合物の精製法 |
WO1999053916A1 (en) * | 1998-04-21 | 1999-10-28 | Mitsui Norin Co., Ltd. | Anti-chlamydia agents |
Non-Patent Citations (2)
Title |
---|
HARA M. ET AL: "Cha Polyphenol Rui o Kinosei to Shokuhin eno Oyo", NEW FOOD INDUSTRY, vol. 32, no. 2, 1990, XP002995687 * |
See also references of EP1770090A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1891862A1 (en) * | 2006-07-24 | 2008-02-27 | Unilever Plc | Beverage precursor |
WO2008012280A3 (en) * | 2006-07-24 | 2008-03-13 | Unilever Plc | Beverage precursor and process for the manufacture thereof |
CN101686701B (zh) * | 2007-05-24 | 2012-07-04 | 花王株式会社 | 精制绿茶提取物 |
CN114534470A (zh) * | 2022-03-23 | 2022-05-27 | 广东安嘉洁环保服务有限公司 | 一种生态空间净化溶液及其制备方法 |
CN114534470B (zh) * | 2022-03-23 | 2023-05-26 | 广东安嘉洁环保服务有限公司 | 一种生态空间净化溶液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4702824B2 (ja) | 2011-06-15 |
JP2006036645A (ja) | 2006-02-09 |
EP1770090B1 (en) | 2016-07-20 |
EP1770090A4 (en) | 2008-01-16 |
US20070292544A1 (en) | 2007-12-20 |
EP1770090A1 (en) | 2007-04-04 |
US20100069429A1 (en) | 2010-03-18 |
ES2586417T3 (es) | 2016-10-14 |
US7763291B2 (en) | 2010-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7763291B2 (en) | Tea polyphenol composition and method for producing the same | |
Yang et al. | Effects of different steeping methods and storage on caffeine, catechins and gallic acid in bag tea infusions | |
WO2009014758A1 (en) | Process of making theaflavins enriched tea extract | |
CN101454015A (zh) | 包含绿茶种的提取物和方法 | |
JP2007001893A (ja) | カテキン組成物及びその製造方法 | |
WO2002022148A1 (fr) | Polyphenol de la pomme sauvage et procede de production correspondant | |
US7666452B2 (en) | Beverage comprising cathechins and caffeine | |
WO2001056586A1 (en) | Method for the isolation of caffeine-free catechins from green tea | |
JP3808494B2 (ja) | プロアントシアニジン高含有物の製造方法 | |
WO2006014499A1 (en) | Cinnamon extract enriched for polyphenols and methods of preparing same | |
WO2011074538A1 (ja) | 茶ポリフェノール及びその製造方法 | |
RU2519640C2 (ru) | Способ приготовления полифенольных экстрактов из листьев шпината | |
CN106954829A (zh) | 一种超微茶粉果冻及其制作方法 | |
JP7488831B2 (ja) | テアフラビンを含む脂肪細胞の分化促進用組成物 | |
KR100307437B1 (ko) | 녹차로부터항암성분의추출및정제공정 | |
CN109965049B (zh) | 一种从绿茶中分离提取有效成分的制备方法 | |
JPH07238078A (ja) | ポリフェノール化合物の精製法 | |
JP3001283B2 (ja) | 消臭剤およびその製造方法 | |
JP2009221158A (ja) | 中性脂肪低減剤および体脂肪増加抑制剤 | |
JPH0314572A (ja) | 植物体のカテキン類の製造方法 | |
CN110721128A (zh) | 桑白皮提取物及其制备方法 | |
US20080249163A1 (en) | Process For Producing Product Containing Proanthocyanidin in High Proportion | |
CN113292717B (zh) | 一种基于啤酒花提取的酪氨酸酶抑制剂及其提取方法和应用 | |
JP5232979B2 (ja) | コレステロール低減剤 | |
KR101852441B1 (ko) | 차의 맛, 향 및 용해성이 우수한 차 추출물 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REEP | Request for entry into the european phase |
Ref document number: 2004772013 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004772013 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11631444 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004772013 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11631444 Country of ref document: US |